QuantRx Biomedical Corporation (QTXB)

USD 0.0

(0.0%)

Market Cap (In USD)

39.34 Thousand

Revenue (In USD)

-

Net Income (In USD)

-

Avg. Volume

852.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.0E-5-0.0079
PE
-
EPS
-
Beta Value
-2.042
ISIN
US74765N1090
CUSIP
74765N109
CIK
820608
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Dr. Shalom Z. Hirschman M.D.
Employee Count
-
Website
-
Ipo Date
2004-07-02
Details
QuantRx Biomedical Corporation engages in the development and commercialization of patented miniform pads (PADs) and PAD based over-the-counter products in the United States. It is also developing genomic diagnostics for the laboratory market based on its lateral flow patents, including RapidSense technology, a one-step lateral flow test. The company's PAD products are used for the treatment of hemorrhoids, minor vaginal infection, urinary incontinence, general catamenial uses, and other medical needs. Its products include InSync, a feminine hygienic interlabial pad; Unique miniform, a treated pad for the temporary relief of the itch and discomfort associated with hemorrhoids and minor vaginal infection, as well as an untreated pad for the daily protection of light urinary, vaginal, or anal leakage; and other treated miniform products. QuantRx Biomedical Corporation was incorporated in 1986 and is based in Tualatin, Oregon.